Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Journal of Ovarian Research
Published in: Journal of Ovarian Research 1/2017

Open Access 01-12-2017 | Research

Collagen triple helix repeat containing 1 (CTHRC1) activates Integrin β3/FAK signaling and promotes metastasis in ovarian cancer

Authors: Biying Guo, Huan Yan, Luying Li, Kemin Yin, Fang Ji, Shu Zhang

Published in: Journal of Ovarian Research | Issue 1/2017

Login to get access

Abstract

Background

Metastasis is the major cause of morbidity and mortality in patients with epithelial ovarian cancer (EOC), however the mechanisms that underline this process are poorly understood. Collagen triple helix repeat containing-1 (CTHRC1) is a 28-kDa secreted protein reported to be involved in vascular remodeling, bone formation and morphogenesis. This study aimed to investigate the role of CTHRC1 in promoting the metastasis of EOC and to elucidate the underlying molecular mechanisms.

Methods

The biologic functions of CTHRC1 in metastasis were validated both in vivo and in vitro experiments. The phosphor-antibody microarray analysis and Co-immunoprecipitation were performed to detect and identify the integrin β3/FAK signaling pathway that mediated the function of CTHRC1. Seventy two EOC samples were analyzed for association between CTHRC1/integrin β3 expression and patient clinicopathological features.

Results

We demonstrated that CTHRC1 enhances the biological behavior of EOC including cell migration, invasion, as well as its adhesion capability to cell-extracellular matrix in vitro. Additionally, CTHRC1 promoted metastatic spread of EOC cells in an i.p. ovarian xenograft model and this phenotype was primarily ascribed to the activation of integrin/FAK signaling. Mechanistically, we determined that FAK were phosphorylated on Tyr397, and were activated by integrin β3, which is important for the CTHRC1-mediated migratory and invasive ability of EOC cells in vitro and i.p. metastasis. In addition, we found that attenuated CTHRC1/integrin β3 expression predicted a poor prognostic phenotype and advanced clinical stage of EOC.

Conclusions

Our results suggest that CTHRC1, a newly identified regulator of i.p. metastasis through activation of integrin β3/FAK signaling in EOC, may represent a potential therapeutic target for ovarian cancer.
Appendix
Available only for authorised users
Literature
1.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRefPubMed
2.
Xu H, Ma Y, Zhang Y, Pan Z, Lu Y, Liu P, et al. Identification of Cathepsin K in the peritoneal metastasis of ovarian carcinoma using in-silico, gene expression analysis. J Cancer. 2016;7:722–9.CrossRefPubMedPubMedCentral
3.
Kenny HA, Nieman KM, Mitra AK, Lengyel E. The first line of intra-abdominal metastatic attack: breaching the mesothelial cell layer. Cancer Discov. 2011;1:100–2.CrossRefPubMedPubMedCentral
4.
Weidle UH, Birzele F, Kollmorgen G, Rueger R. Mechanisms and targets involved in dissemination of ovarian cancer. Cancer Genomics Proteomics. 2016;13:407–23.CrossRefPubMed
5.
Naora H, Montell DJ. Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer. 2005;5:355–66.CrossRefPubMed
6.
Crotti S, Piccoli M, Rizzolio F, Giordano A, Nitti D, Agostini M. Extracellular matrix and colorectal cancer: how surrounding microenvironment affects cancer cell behavior? J Cell Physiol. 2017;232:967–75.CrossRefPubMed
7.
Zhou XM, Zhang H, Han X. Role of epithelial to mesenchymal transition proteins in gynecological cancers: pathological and therapeutic perspectives. Tumour Biol. 2014;35:9523–30.CrossRefPubMed
8.
Cai Q, Yan L, Xu Y. Anoikis resistance is a critical feature of highly aggressive ovarian cancer cells. Oncogene. 2015;34:3315–24.CrossRefPubMed
9.
Ricciardelli C, Lokman NA, Ween MP, Oehler MK. WOMEN IN CANCER THEMATIC REVIEW: ovarian cancer-peritoneal cell interactions promote extracellular matrix processing. Endocr Relat Cancer. 2016;23:T155–68.CrossRefPubMed
10.
Yu H, Zhang L, Liu P. CXCR7 Signaling induced epithelial-mesenchymal transition by AKT and ERK pathways in epithelial ovarian carcinomas. Tumour Biol. 2015;36:1679–83.CrossRefPubMed
11.
He LC, Gao FH, Xu HZ, Zhao S, Ma CM, Li J, et al. Ikaros inhibits proliferation and, through upregulation of slug, increases metastatic ability of ovarian serous adenocarcinoma cells. Oncol Rep. 2012;28:1399–405.CrossRefPubMed
12.
Roomi MW, Kalinovsky T, Niedzwiecki A, Rath M. Modulation of uPA, MMPs and their inhibitors by a novel nutrient mixture in human colorectal, pancreatic and hepatic carcinoma cell lines. Int J Oncol. 2015;47:370–6.CrossRefPubMed
13.
Beausejour M, Noel D, Thibodeau S, Bouchard V, Harnois C, Beaulieu JF, et al. Integrin/Fak/Src-mediated regulation of cell survival and anoikis in human intestinal epithelial crypt cells: selective engagement and roles of PI3-K isoform complexes. Apoptosis. 2012;17:566–78.CrossRefPubMedPubMedCentral
14.
Mitra SK, Schlaepfer DD. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol. 2006;18:516–23.CrossRefPubMed
15.
16.
Spina A, Di Maiolo F, Esposito A, Sapio L, Chiosi E, Sorvillo L, et al. cAMP elevation down-regulates beta3 Integrin and focal adhesion Kinase and inhibits Leptin-induced migration of MDA-MB-231 breast cancer cells. Biores Open Access. 2012;1:324–32.CrossRefPubMedPubMedCentral
17.
Sawada K, Ohyagi-Hara C, Kimura T, Morishige K. Integrin inhibitors as a therapeutic agent for ovarian cancer. J Oncol. 2012;2012:915140.CrossRefPubMed
18.
Luo C, Lim JH, Lee Y, Granter SR, Thomas A, Vazquez F, et al. A PGC1alpha-mediated transcriptional axis suppresses melanoma metastasis. Nature. 2016;537:422–6.CrossRefPubMedPubMedCentral
19.
Pyagay P, Heroult M, Wang Q, Lehnert W, Belden J, Liaw L, et al. Collagen triple helix repeat containing 1, a novel secreted protein in injured and diseased arteries, inhibits collagen expression and promotes cell migration. Circ Res. 2005;96:261–8.CrossRefPubMed
20.
Liu W, Fu XL, Yang JY, Yang MW, Tao LY, Liu DJ, et al. Elevated expression of CTHRC1 predicts unfavorable prognosis in patients with pancreatic ductal adenocarcinoma. Am J Cancer Res. 2016;6:1820–7.PubMedPubMedCentral
21.
Chen YL, Wang TH, Hsu HC, Yuan RH, Jeng YM. Overexpression of CTHRC1 in hepatocellular carcinoma promotes tumor invasion and predicts poor prognosis. PLoS One. 2013;8:e70324.CrossRefPubMedPubMedCentral
22.
Ke Z, He W, Lai Y, Guo X, Chen S, Li S, et al. Overexpression of collagen triple helix repeat containing 1 (CTHRC1) is associated with tumour aggressiveness and poor prognosis in human non-small cell lung cancer. Oncotarget. 2014;5:9410–24.CrossRefPubMedPubMedCentral
23.
Hou M, Cheng Z, Shen H, He S, Li Y, Pan Y, et al. High expression of CTHRC1 promotes EMT of epithelial ovarian cancer (EOC) and is associated with poor prognosis. Oncotarget. 2015;6:35813–29.PubMedPubMedCentral
24.
Ma MZ, Zhuang C, Yang XM, Zhang ZZ, Ma H, Zhang WM, et al. CTHRC1 Acts as a prognostic factor and promotes invasiveness of gastrointestinal stromal tumors by activating Wnt/PCP-rho signaling. Neoplasia. 2014;16:265–78. 278 e261-213CrossRefPubMedPubMedCentral
25.
Park EH, Kim S, Jo JY, Kim SJ, Hwang Y, Kim JM, et al. Collagen triple helix repeat containing-1 promotes pancreatic cancer progression by regulating migration and adhesion of tumor cells. Carcinogenesis. 2013;34:694–702.CrossRefPubMed
26.
Zhang R, Cao Y, Bai L, Zhu C, Li R, He H, et al. The collagen triple helix repeat containing 1 facilitates hepatitis B virus-associated hepatocellular carcinoma progression by regulating multiple cellular factors and signal cascades. Mol Carcinog. 2015;54:1554–66.CrossRefPubMed
27.
Zhang YM, Dai BL, Zheng L, Zhan YZ, Zhang J, Smith WW, et al. A novel angiogenesis inhibitor impairs lovo cell survival via targeting against human VEGFR and its signaling pathway of phosphorylation. Cell Death Dis. 2012;3:e406.CrossRefPubMedPubMedCentral
28.
Zhang Y, Zhao FJ, Chen LL, Wang LQ, Nephew KP, Wu YL, et al. MiR-373 targeting of the Rab22a oncogene suppresses tumor invasion and metastasis in ovarian cancer. Oncotarget. 2014;5:12291–303.CrossRefPubMedPubMedCentral
29.
Galbavy W, Kaczocha M, Puopolo M, Liu L, Rebecchi MJ. Neuroimmune and neuropathic responses of spinal cord and dorsal root ganglia in middle age. PLoS One. 2015;10:e0134394.CrossRefPubMedPubMedCentral
30.
Tafani M, Pucci B, Russo A, Schito L, Pellegrini L, Perrone GA, et al. Modulators of HIF1alpha and NFkB in cancer treatment: is it a rational approach for controlling malignant progression? Front Pharmacol. 2013;4:13.CrossRefPubMedPubMedCentral
31.
Wen W, Liang W, Wu J, Kowolik CM, Buettner R, Scuto A, et al. Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer. Mol Cancer Ther. 2014;13:3037–48.CrossRefPubMedPubMedCentral
32.
LeClair R, Lindner V. The role of collagen triple helix repeat containing 1 in injured arteries, collagen expression, and transforming growth factor beta signaling. Trends Cardiovasc Med. 2007;17:202–5.CrossRefPubMed
33.
Ip W, Wellman-Labadie O, Tang L, Su M, Yu R, Dutz J, et al. Collagen triple helix repeat containing 1 promotes melanoma cell adhesion and survival. J Cutan Med Surg. 2011;15:103–10.CrossRefPubMed
34.
Liu G, Sengupta PK, Jamal B, Yang HY, Bouchie MP, Lindner V, et al. N-glycosylation induces the CTHRC1 protein and drives oral cancer cell migration. J Biol Chem. 2013;288:20217–27.CrossRefPubMedPubMedCentral
35.
Heerkens EH, Quinn L, Withers SB. Heagerty AM.Beta Integrins mediate FAK Y397 autophosphorylation of resistance arteries during eutrophic inward remodeling in hypertension. J Vasc Res. 2014;51:305–14.CrossRefPubMedPubMedCentral
36.
Chen J, Zhang J, Zhao Y, Li J, Fu M. Integrin beta3 down-regulates invasive features of ovarian cancer cells in SKOV3 cell subclones. J Cancer Res Clin Oncol. 2009;135:909–17.CrossRefPubMed
37.
Lane D, Goncharenko-Khaider N, Rancourt C, Piche A. Ovarian cancer ascites protects from TRAIL-induced cell death through alphavbeta5 integrin-mediated focal adhesion kinase and Akt activation. Oncogene. 2010;29:3519–31.CrossRefPubMed
38.
Xiong S, Klausen C, Cheng JC, Zhu H, Leung PC. Activin B induces human endometrial cancer cell adhesion, migration and invasion by up-regulating integrin beta3 via SMAD2/3 signaling. Oncotarget. 2015;6:31659–73.CrossRefPubMedPubMedCentral
39.
Salvo E, Garasa S, Dotor J, Morales X, Pelaez R, Altevogt P, et al. Combined targeting of TGF-beta1 and integrin beta3 impairs lymph node metastasis in a mouse model of non-small-cell lung cancer. Mol Cancer. 2014;13:112.CrossRefPubMedPubMedCentral
40.
Yang YW, Chen HC, Jen WF, Liu LY, Chang MC. Comparative Transcriptome analysis of shoots and roots of TNG67 and TCN1 Rice seedlings under cold stress and following subsequent recovery: insights into metabolic pathways, Phytohormones, and transcription factors. PLoS One. 2015;10:e0131391.CrossRefPubMedPubMedCentral
41.
Slack-Davis JK, Martin KH, Tilghman RW, Iwanicki M, Ung EJ, Autry C, et al. Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem. 2007;282:14845–52.CrossRefPubMed
42.
Dao P, Smith N, Scott-Algara D, Garbay C, Herbeuval JP, Chen H. Restoration of TRAIL-induced apoptosis in resistant human pancreatic cancer cells by a novel FAK inhibitor, PH11. Cancer Lett. 2015;360:48–59.CrossRefPubMed
Metadata
Title
Collagen triple helix repeat containing 1 (CTHRC1) activates Integrin β3/FAK signaling and promotes metastasis in ovarian cancer
Authors
Biying Guo
Huan Yan
Luying Li
Kemin Yin
Fang Ji
Shu Zhang
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Journal of Ovarian Research / Issue 1/2017
Electronic ISSN: 1757-2215
DOI
https://doi.org/10.1186/s13048-017-0358-8

Other articles of this Issue 1/2017

Journal of Ovarian Research 1/2017 Go to the issue

Research

What we learned from extended culture of ‘rejected’ day-3 cleavage stage embryos: a prospective cohort study

Research

Biological effects of combined resveratrol and vitamin D3 on ovarian tissue

Research

Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair

Research

BRCA1 expression, proliferative and apoptotic activities in ovarian epithelial inclusions

Research

Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy

Research

Naturally occurring anti-glycan antibodies binding to Globo H-expressing cells identify ovarian cancer patients